In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going ...
In the quest to match its predecessor Soliris, Alexion's Ultomiris just notched a win in the autoimmune disorder myasthenia gravis. Alexion is trumpeting data showing Ultomiris met its primary ...
Smarting from a patent defeat for cash cow Soliris in Europe, Alexion has dulled the pain with a phase 3 readout that sets up new filings for follow-up Ultomiris. The top-line data comes from a study ...
- ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients receiving SOLIRIS ® (eculizumab) - BOSTON--(BUSINESS WIRE)--Alexion ...
(Reuters) - The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's treatment for a second rare blood disorder, the company said. The treatment, Ultomiris, has already ...
BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS® (ravulizumab-cwvz) in a subset of adults with ...
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending ...
There are plenty of promising biotech stocks for investors to sift through right now. One of these companies is Alexion Pharmaceuticals (ALXN +0.00%), a developer of treatments for rare diseases that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback